Pharmabiz19h
Pfizer receives US FDA approval for its RSV vaccine Abrysvo for adults aged 18 to 59 at increased risk for disease
In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine. Variations in the F protein sequence among RSV-A and ...
PharmTech1d
FDA Approves RSV Vaccine
Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...
Armed robbery in Revesby1d
FDA Clears Pfizer RSV Vaccine for At-Risk Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...
MedPage Today5d
Novel Monoclonal Antibody Protects Infants Against RSV
Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...